Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462460 · ClinicalTrials.gov registry record
Rapid Pancreatic and Ovarian Screening MR Imaging With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI
A clinical trial of Screening Breast MRI in Patients Who Are BRCA Mutation Carriers, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 63
- Enrollment target
- 1
- Study location
NCT02462460: Active study of Screening Breast MRI in Patients Who Are BRCA Mutation Carriers, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02462460 is a study of Screening Breast MRI in Patients Who Are BRCA Mutation Carriers that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 63 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462460, a study of Screening Breast MRI in Patients Who Are BRCA Mutation Carriers, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to create a rapid scan of the pancreas and ovaries that could be used in the future to screen patients at risk for pancreatic or ovarian cancers. Currently, Magnetic Resonance Imaging (MRI) examinations of the pancreas and ovaries can last 30-45 minutes each. The investigators hope to create a rapid pancreatic and ovarian MRI evaluation that can be used as a screening tool that is completed in approximately 15 minutes. They will compare different tools available on modern MRI scanners to see which one reliably offers high quality images of the pancreas and ovaries.
Primary Outcome
The images will be evaluated qualitatively for image quality from 1 to 5 with 5 = not adequate and 1 = adequate image quality by two radiologists in consensus. If both radiologists give a score of 1, the sequence will be considered to be adequate in image quality. Quantitative measurements of SNR will be performed on the pancreatic head, body and tail, and ovarian tissue by region of interest (ROI) analysis. Final acquisition times and spatial resolution for each sequence will be recorded.
Conditions Studied
Interventions
- DEVICE MRI
- BEHAVIORAL Optional Screening Questionnaire
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-06 |
| Est. Completion | 2026-06 |
What the registry record for NCT02462460 still lists
NCT02462460 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 1 condition, with Screening Breast MRI in Patients Who Are BRCA Mutation Carriers appearing as the primary indexed condition, and to 2 interventions - of which MRI is the first listed.
NCT02462460 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02462460 about?
NCT02462460 is a clinical study titled "Rapid Pancreatic and Ovarian Screening MR Imaging With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI". The purpose of this study is to create a rapid scan of the pancreas and ovaries that could be used in the future to screen patients at risk for pancreatic or ovarian cancers. Currently, Magnetic Resonance Imaging (MRI) examinations of the pancreas and ovaries can last 30-45 minutes each. The investi...
What is the current status of trial NCT02462460?
This trial is currently active not recruiting. The enrollment target is 63 participants. The study started on 2015-06. Estimated completion is 2026-06.
What conditions does trial NCT02462460 study?
This clinical trial studies the following conditions: Screening Breast MRI in Patients Who Are BRCA Mutation Carriers.
What interventions are being tested in trial NCT02462460?
The interventions under investigation include: MRI (DEVICE), Optional Screening Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT02462460?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02462460 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia